Prophylactic treatment for hypertension and seizure in a case of allogeneic hematopoietic stem cell transplantation after posterior reversible encephalopathy syndrome

Fukuyama T, Tanaka M, Nakazawa Y, Motoki N, Inaba Y, Higuchi T, Koike K. Prophylactic treatment for hypertension and seizure in a case of allogeneic hematopoietic stem cell transplantation after posterior reversible encephalopathy syndrome. Pediatr Transplantation 2011: 15: E169–E173. © 2010 John Wi...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric transplantation 2011-12, Vol.15 (8), p.E169-E173
Main Authors: Fukuyama, Tetsuhiro, Tanaka, Miyuki, Nakazawa, Yozo, Motoki, Noriko, Inaba, Yuji, Higuchi, Tsukasa, Koike, Kenichi
Format: Article
Language:English
Subjects:
Anticonvulsants - therapeutic use
Antihypertensive Agents - therapeutic use
antihypertensive therapy
Brain - diagnostic imaging
Brain - pathology
Child
hematopoietic stem cell transplantation
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Hypertension - etiology
Hypertension - prevention & control
leukemia
Magnetic Resonance Imaging
Male
Posterior Leukoencephalopathy Syndrome - diagnosis
Posterior Leukoencephalopathy Syndrome - etiology
Posterior Leukoencephalopathy Syndrome - prevention & control
posterior reversible encephalopathy syndrome
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Radiography
Seizures - etiology
Seizures - prevention & control
Transplantation, Homologous
Unrelated Donors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fukuyama T, Tanaka M, Nakazawa Y, Motoki N, Inaba Y, Higuchi T, Koike K. Prophylactic treatment for hypertension and seizure in a case of allogeneic hematopoietic stem cell transplantation after posterior reversible encephalopathy syndrome. Pediatr Transplantation 2011: 15: E169–E173. © 2010 John Wiley & Sons A/S. :  A six‐yr‐old boy developed PRES after induction chemotherapy for the relapse of acute lymphoblastic leukemia. Two months after PRES, he underwent BMT from an unrelated HLA‐mismatched donor. There were many risk factors for PRES in the BMT including the long‐term use of FK506 and methylprednisolone, grade III graft‐versus‐host disease, thrombotic microangiopathy, and sepsis. Prophylactic treatment for hypertension with nicardipine in conjunction with close monitoring of the magnesium level and the use of valproic acid might be an effective management approach to prevent post‐transplant PRES.
ISSN:1397-3142
1399-3046
DOI:10.1111/j.1399-3046.2010.01358.x